Article Text

Download PDFPDF
Oral prednisolone reduced exacerbation of symptoms in children with virally induced lower airway disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In children 6–35 months of age with virally induced lower airway disease (VILAD), is oral prednisolone (OP) more effective than placebo for reducing exacerbation of symptoms, hospital length of stay, and duration of symptoms?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Paediatrics ★★★★★☆☆ Respirology ★★★★★☆☆ Emergency medicine ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (participants and healthcare providers).*

Embedded ImageFollow up period:

14 days.

Embedded ImageSetting:

a university hospital in Tampere, Finland.

Embedded ImagePatients:

248 children 6–35 years of age who presented to a paediatric emergency department with VILAD (acute tachypnoea, wheezing, or use of accessory respiratory muscles). Exclusion critera included asthma, inspiratory stridor, epiglottitis, foreign body aspiration, and chronic pulmonary diseases. 230 …

View Full Text


  • * See glossary.

  • For correspondence: Dr P Csonka, Tampere University Hospital, University of Tampere, Tampere, Finland.

  • Sources of funding: 7 funding agencies.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd